Bellevue Group’s Avidity Biosciences RNAM Stock Holding History

Bellevue Group’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,630,969	Closed	-$190M	–	187
2025 Q4	$190M	Buy	2,630,969 +478,107	+22%	+$30.9M	3.6%	6
2025 Q3	$93.8M	Buy	+2,152,862	New	+$87M	1.95%	16

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Bellevue Group's RNAM Position: Q1 2026 in Review

Bellevue Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,630,969 shares — an estimated $190M sold.

Bellevue Group first reported a position in RNAM in Q3 2025 and held it in 2 quarters. The position peaked at $190M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Bellevue Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 2,630,969 Avidity Biosciences shares in Q1 2026, an estimated $190M.
Bellevue Group first reported a position in Avidity Biosciences in Q3 2025 and held it in 2 quarters.
Bellevue Group's Avidity Biosciences position peaked at $190M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.